.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Farmers Insurance
Boehringer Ingelheim
Deloitte
Chinese Patent Office
US Army
Argus Health
Cipla
UBS
Mallinckrodt

Generated: December 15, 2017

DrugPatentWatch Database Preview

Allergan Sales Llc Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN SALES LLC, and when can generic versions of ALLERGAN SALES LLC drugs launch?

ALLERGAN SALES LLC has thirty approved drugs.

There are twenty US patents protecting ALLERGAN SALES LLC drugs.

There are two hundred and twenty-eight patent family members on ALLERGAN SALES LLC drugs in thirty countries and fifty-nine supplementary protection certificates in twelve countries.

Summary for Allergan Sales Llc

International Patents:228
US Patents:20
Tradenames:27
Ingredients:21
NDAs:30
Drug Master File Entries: 1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Allergan Sales LlcTRELSTARtriptorelin pamoateINJECTABLE;INTRAMUSCULAR021288-001Jun 29, 2001RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcHYDROXYPROGESTERONE CAPROATEhydroxyprogesterone caproateINJECTABLE;INJECTION017439-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-011Jul 9, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcCRINONEprogesteroneGEL;VAGINAL020701-001Jul 31, 1997RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-007Feb 27, 2007RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcDALVANCEdalbavancin hydrochloridePOWDER;IV (INFUSION)021883-001May 23, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcTRETINOINtretinoinCREAM;TOPICAL202209-001Oct 11, 2012DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-006Oct 27, 2006ABRXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcSAVELLAmilnacipran hydrochlorideTABLET;ORAL022256-003Jan 14, 2009ABRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Allergan Sales LlcCONDYLOXpodofiloxGEL;TOPICAL020529-001Mar 13, 1997RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Allergan Sales Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-003Jul 3, 1996► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-006Oct 27, 2006► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-008Apr 20, 2007► Subscribe► Subscribe
Allergan Sales LlcTRELSTARtriptorelin pamoateINJECTABLE;INTRAMUSCULAR020715-001Jun 15, 2000► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-007Feb 27, 2007► Subscribe► Subscribe
Allergan Sales LlcALORAestradiolFILM, EXTENDED RELEASE;TRANSDERMAL020655-003Dec 20, 1996► Subscribe► Subscribe
Allergan Sales LlcALORAestradiolFILM, EXTENDED RELEASE;TRANSDERMAL020655-004Apr 5, 2002► Subscribe► Subscribe
Allergan Sales LlcALORAestradiolFILM, EXTENDED RELEASE;TRANSDERMAL020655-001Dec 20, 1996► Subscribe► Subscribe
Allergan Sales LlcTRELSTARtriptorelin pamoateINJECTABLE;INTRAMUSCULAR021288-001Jun 29, 2001► Subscribe► Subscribe
Allergan Sales LlcKADIANmorphine sulfateCAPSULE, EXTENDED RELEASE;ORAL020616-005Mar 9, 2001► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALLERGAN SALES LLC drugs

Drugname Dosage Strength Tradename Submissiondate
oxybutynin chlorideGel10%GELNIQUE6/19/2014
milnacipran hydrochlorideTablets12.5 mg, 25 mg, 50 mg, and 100 mgSAVELLA1/14/2013
silodosinCapsules4 mg and 8 mgRAPAFLO10/9/2012
oxybutyninTransdermal System Extended-re3.9 mg/24 hrsOXYTROL8/19/2008

Non-Orange Book Patents for Allergan Sales Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,652,491Transdermal compositions for anticholinergic agents► Subscribe
7,404,965Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels► Subscribe
8,980,309Transdermal testosterone formulation for minimizing skin residues► Subscribe
7,335,379Transdermal pharmaceutical formulation for minimizing skin residues► Subscribe
6,635,675 Method of treating chronic fatigue syndrome► Subscribe
7,470,433Formulations for transdermal or transmucosal application► Subscribe
7,087,241Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy► Subscribe
8,980,290Transdermal compositions for anticholinergic agents► Subscribe
7,915,246Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain► Subscribe
7,387,788Pharmaceutical compositions of nicotine and methods of use thereof► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Allergan Sales Llc Drugs

Country Document Number Estimated Expiration
Denmark1565136► Subscribe
Russian Federation2008142899► Subscribe
China1964736► Subscribe
Canada2564112► Subscribe
BrazilPI0510269► Subscribe
Cyprus1111498► Subscribe
Mexico338166► Subscribe
Spain2283665► Subscribe
Morocco31720► Subscribe
China1671368► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Allergan Sales Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
49/2008Austria► SubscribePRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON
330Luxembourg► SubscribeCERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
C0002Belgium► SubscribePRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
00043Netherlands► SubscribePRODUCT NAME: ALITRETINOIN; NAT. REGISTRATION NO/DATE: EU/1/00/149/001 20001011; FIRST REGISTRATION: EU/1/00/149/001 20001011
C/GB02/037United Kingdom► SubscribePRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
C/GB10/031United Kingdom► SubscribePRODUCT NAME: SILODOSIN, OPTIONALLY IN A FORM OF A PHARMACEUTICAL ACCEPTABLE SALT; REGISTERED: UK EU/1/09/607/001-014 20100129; UK EU/1/09/608/001-014 20100129
C0033France► SubscribePRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
C0025Belgium► SubscribePRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
C/GB04/032United Kingdom► SubscribePRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Federal Trade Commission
Chinese Patent Office
Daiichi Sankyo
UBS
Merck
Julphar
Teva
QuintilesIMS
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot